Internal Medicine, Medical Oncology · Baltimore, MD
NPI
1255488201
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1800 Orleans St
Baltimore, MD, 21287
Phone (314) 747-1171
Groups this clinician bills Medicare through
Medicare paid, 2024
$39K
631 services
Medicare patients, 2024
189
Average age 74
Drug cost, 2024
$2.7M
384 prescriptions
Company payments, 2025
$20K
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nina D Wagner-Johnston was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 198 times for 130 patients. In total Nina D Wagner-Johnston billed 631 services in 16 codes, and Medicare paid $39K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-12.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 198 | 130 | $13.31 | $2,635 |
| 99215 Office E&M - Established | Facility | 133 | 88 | $113.45 | $15K |
| 99214 Office E&M - Established | Facility | 101 | 85 | $69.84 | $7,054 |
| 99213 Office E&M - Established | Facility | 31 | 27 | $54.46 | $1,688 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 26 | 16 | $26.01 | $676 |
| 99233 Hospital E&M - Subsequent | Facility | 23 | 13 | $95.82 | $2,204 |
| 99205 Office E&M - New | Facility | 16 | 16 | $141.01 | $2,256 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 13 | 11 | $13.66 | $178 |
By year: 2022 $45K for 473 services; 2023 $43K for 484 services; 2024 $39K for 631 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nina D Wagner-Johnston prescribed most often to Medicare patients was Calquence (Acalabrutinib Maleate), with 42 prescriptions and refills. In total Nina D Wagner-Johnston wrote 384 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | 42 | 42 | Under 11 | $659K |
| Brukinsa Zanubrutinib | 40 | 40 | Under 11 | $599K |
| Jaypirca Pirtobrutinib | 27 | 27 | Under 11 | $582K |
| Prednisone Generic | 27 | 27 | 13 | $66.9 |
| Venclexta Venetoclax | 27 | 27 | Under 11 | $354K |
| Valacyclovir Valacyclovir Hcl | 24 | 28 | Under 11 | $862 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 22 | 24 | Under 11 | $34.51 |
| Ondansetron Hcl Generic | 21 | 21 | 14 | $77.42 |
| Prochlorperazine Maleate Generic | 18 | 18 | 12 | $115 |
| Oxycodone Hcl Generic | 16 | 16 | Under 11 | $116 |
| Allopurinol Generic | 13 | 13 | Under 11 | $73.41 |
| Imbruvica Ibrutinib | 11 | 11 | Under 11 | $258K |
Brand drugs: 165 claims; generic drugs: 219 claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nina D Wagner-Johnston $20K ($18K in general payments such as food, travel and fees and $1,345 for research) from 4 companies. The largest payer was Genentech, Inc. with $18K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.